Developing Next-Gen
Treatments for OA
Innovative clinical-stage biotech company leveraging proprietary liposomal technologies for treatment of osteoarthritis.
About Us
We were founded in 2008 by a renowned liposome scientist to commercialize innovative patented lipid-based technologies. Our vision is to improve quality of life for the millions who suffer from OA through novel, more effective and more durable treatments.
+
Learn More
Our Lead Product: MM-II
Not a steroid. Not hyaluronic acid. A new way to treat OA. Currently in Phase 3 clinical development.
Non-opioid intra-articular injection shown in clinical trials to reduce OA pain for at least 6 months following a single injection. Safe, effective and durable.
News
See All
April, 2025
Sun Pharma and Moebius Medical announce dual publications on MM-II’s phase 2b clinical trial results and mechanism of action in Osteoarthritis and Cartilage
Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA models featured in two peer-reviewed articles. New data on MM-II presented at the OARSI 2025 World Conference on Osteoarthritis.
+
Learn More
December, 2024
MM-II Granted fast track designation by FDA
Sun Pharma and Moebius Medical Announce Fast Track Designation Granted for MM-II for the Treatment of Osteoarthritis Knee Pain
+
Learn More
June, 2024
Oral presentation at EULAR 2024
Demonstrating durability of pain relief after a single injection of MM-II in patients with painful knee osteoarthritis
+
Learn More
March, 2023
Moebius Medical at OARSI 2023
Moebius Medical announced that Dr. Tomas J. Schnitzer (Northwestern University) will present Phase 2b trial results at OARS, while CEO Moshe Weinstein will give a corporate update at the pre-congress Clinical Trial Symposium. Additionally, two posters on trial results and MM-II’s mechanism of action were accepted at OARSI.
March, 2023
Presentation at EULAR 2023
Moebius Medical announced today that its abstract titled “INTRA-ARTICULAR MM-II, A NOVEL SUSPENSION OF LARGE EMPTY MULTILAMELLAR LIPOSOMES, IN PAINFUL KNEE OSTEOARTHRITIS: A 26 WEEK PHASE 2B RANDOMIZED TRIAL”, has been accepted for presentation in a poster tour at EULAR 2023.
March, 2023
MM-II Showed durable Pain relief in global phase 2b study
Moebius Medical and Sun Pharma today announced the results of the global MM-II phase clinical study
+
Learn More
February, 2021
First patient dosed in phase II study
Moebius Medical Announces Dosing of First Patient in Global Phase IIb Clinical Trial of MM-II
+
Learn More
December, 2020
FDA Clearance of IND
Moebius Medical Announces FDA Clearance of IND Application for Phase IIb Clinical Trial of MM-II, a Novel Treatment for Knee Osteoarthritis Pain
+
Learn More
December, 2020
Sun Pharma & Moebius Medical signed a licensing agreement
Sun Pharma & Moebius Medical Sign Exclusive Global Licensing Deal to Develop Novel Liposomal Non-opioid Pain Product for Osteoarthritis
+
Learn More
April, 2020
Abstract accepted to OARSI 2020
Moebius Announces Acceptance of Abstract to OARSI 2020 Congress Showing MM-II’s Ability to Coat Cartilage in-vivo and Reduce Friction and Wear in ex-vivo Cartilage Models.
OA Pain:
A Clinical Dilemma
OA afflicts over 100 million people globally, and no drug exists that can modify the disease. Steroid- and hyaluronic acid (HA)-based treatments are limited in their effectivity, durability and safety.
+54M
People with OA
in the US
in the US
+100M
People with OA
globally
globally
$6 – $15B
Annual cost of OA healthcare in the US
Contact
Careers
We invite you to join a team bringing hope to 100+ million OA sufferers throughout the world.
We look forward to reviewing your resume. Please contact us via LinkedIn.